Tesla sales slump in first annual revenue drop on record

Group 1: Tesla and Automaker Insights - Tesla announced its first annual sales decline, with fourth quarter sales down 3% year-over-year and the auto segment down 11% [7] - Despite the sales decline, Tesla's fourth quarter earnings exceeded Wall Street expectations, leading to a rise in shares [2] - The company is pivoting towards humanoid robots, with long-term projections suggesting a significant impact on US GDP [2] Group 2: Economic Outlook and Federal Reserve - The Federal Reserve decided to keep interest rates on hold, breaking a streak of three consecutive rate cuts, and indicated rates will remain steady until further data suggests otherwise [5][6] - The Fed raised its assessment of economic growth, noting signs of stabilization in the unemployment rate [5] - CFO of Deutsche Bank expressed confidence that US economic strength will support global economic growth, with sustainable growth rates projected at around 3.5% [3] Group 3: SAP and Cloud Business - SAP met its fourth quarter sales forecasts and anticipates revenue growth in its cloud business of up to 25% in the upcoming year [4] Group 4: Meta and Microsoft Earnings - Meta's shares surged after reporting fourth quarter earnings that surpassed expectations, driven by holiday demand and AI performance gains [8] - Microsoft experienced a sharp decline in shares despite beating earnings expectations, attributed to slower cloud growth and record spending [8] Group 5: Whiz Air Performance - Whiz Air reported third quarter revenue of 1.296 billion, exceeding IBIS estimates of 1.236 billion [9] - The airline expects full-year capacity growth of around 10% and net income projected between -25 million to +25 million for 2026 [10] - CEO highlighted ongoing supply chain challenges and geopolitical issues affecting operations, particularly in the context of the war in Ukraine [12][14] Group 6: RO's Financial Performance - RO reported a core full-year operating profit of 21.8 billion Swiss Francs, slightly below analyst expectations, with a 7% sales growth and 13% operating profit growth [33][34] - The company is optimistic about its pipeline, with plans to launch up to 19 new medicines by the end of the decade [36][39] - Concerns about loss of exclusivity for blockbuster drugs in 2029-2030 were addressed, with management confident in offsetting this through new product launches [38][39] Group 7: Jivodan's Market Position - Jivodan reported a 5.1% growth for the year, maintaining high levels of profitability despite higher input costs and margin compression [58][60] - The company is experiencing strong growth in fine fragrances, particularly in local and regional brands, which are less affected by market fluctuations [64][72] - Jivodan's diversified business model and natural hedges against market volatility position it well for future growth [71]